ACC and MDS Analytical Technologies Collaborate to Offer a Robust LAL Endotoxin Assay Platform
News Jul 09, 2008
Associates of Cape Cod, Inc. (ACC) and MDS Analytical Technologies have announced the launch of ACC's Chromogenic LAL Endotoxin assay kits utilizing MDS Analytical Technologies' SpectraMax® instrument platform and SoftMax® Pro GxP software.
CC and MDS Analytical Technologies collaborated on an FDA 21 CFR part 11 solution for ACC's Chromogenic LAL Endotoxin assay kits. The partnership was based on ACC's validation of MDS Analytical Technologies' VersaMax™ monochromator-based absorbance microplate reader using the SoftMax® Pro GxP software compliant environment.
ACC offers several chromogenic assays: Pyrochrome® and Chromo-LAL for endotoxin detection and Glucatell® to detect (1,3)-beta-D-glucan in industrial applications. All methods are optimized for use in microplate detection systems such as the VersaMax™ reader.
SoftMax® Pro 5 GxP software from MDS Analytical Technologies is the industry standard microplate analysis software, offering extensive data capture and analysis capabilities in a FDA 21 CFR Part 11 compliant environment for MDS Analytical Technologies' SpectraMax® line of microplate readers. It includes features that make it particularly well suited to endotoxin and glucan assays.
ACC President & CEO A.J. Meuse, Ph.D. said, "Partnering with MDS Analytical Technologies, one of the premier bioanalytical instrument companies in the world, further strengthens our ability to meet the variety of instrument and software requirements our customers have for endotoxin and (1,3)-beta-D-glucan analysis. We are pleased to offer our customers the VersaMax™ plate reader which provides additional functionality for product release testing in an FDA 21 CFR Part 11 compliant environment."